Specializing in the manufacturing of approved therapeutics and nutraceuticals in emerging markets with a focus on Africa and Asia

Wholly owned subsidiary preparing to exit stealth and specializing in compounded therapeutics and nutraceuticals with a focus on Inflammaging and telehealth.

Management of Hyperphosphatemia (negotiations to be completed Q1 2023).  Currently undergoing due diligence under a non-binding letter of intent.

Chronic Liver Disease treatment demonstrating anti-fibrotic, immuno-modulating, and anti-inflammatory effects. Entering open label Phase 2b for AIH Q2 2023

Early development stage program uses blockchain and smart contracts to manage and secure prescriptions and electronic health records